While the prevalence of VISA and VRSA remains low, concerns about vancomycin resistance and the lack of a clinical or bacteriological response with as many as 18% of MRSA isolates with a ...

Dalba vancin and oritavancin have shown bactericidal activity against MRSA, VRSA, VRE, and DRSP and are undergoing the final stages of clinical trials (Bradley, 2005; Hoffman-Roberts et al., ...

To make MRSA matters even worse, in 2002, health care workers reported the first cases of vancomycin-resistant MRSA. In other words, even "last-resort" vancomycin doesn't always work. Therein lies ...

Patients colonized with AMR pathogens showed high risk for infection with the same pathogen for up to 2 years, indicating a time window for decolonization interventions.

Methicillin resistant Staphylococcus aureus (MRSA) and Vancomycin resistant Staphylococcus aureus (VRSA) are critical pathogens identified by the WHO for their significant drug resistance.